EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI

키워드

참고문헌 (24)

1. Shepherd FA, "Erlotinib in previously treated non-small-cell lung cancer", N Engl J Med, 353, pp.123~132 (2005)
2. "J Clin Oncol", 2003, 2237~2246
3. Pérez-Soler R, "Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer", J Clin Oncol, 22, pp.3238~3247 (2004)
4. Miller VA, "Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer", J Clin Oncol, 22, pp.1103~1109 (2004)
5. West HL, "Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126", J Clin Oncol, 24, pp.1807~1813 (2006)
6. Pao W, "EGF receptor gene mutations are common in lung cancers from"never smokers"and are associated with sensitivity of tumors to gefitinib and erlotinib", Proc Natl Acad Sci U S A, 101, pp.13306~13311 (2004)
7. Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)
8. Tokumo M, "The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers", Clin Cancer Res, 11, pp.1167~1173 (2005)
9. Yang CH, "Specific EGFR mutations predict treatment outcome of stage IIIB", IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy, 2008, pp.26, 2745~2753
10. Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
11. Fukuoka M, "Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin", paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS), 2011, pp.29, 2866~2874
12. Hlinkova K, "Rapid and efficient detection of EGFR mutations in problematic cytologic specimens by high-resolution melting analysis", Mol Diagn Ther, 15, pp.21~29 (2011)
13. Tsao MS, "Erlotinib in lung cancer - molecular and clinical predictors of outcome", N Engl J Med, 353, pp.133~144 (2005)
14. Cappuzzo F, "Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer", J Natl Cancer Inst, 97, pp.643~655 (2005)
15. Nomura M, "Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers", PLoS Med, 4, pp.125~ (2007)
16. Nie Q, "CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism", Eur J Cancer, 47, pp.1962~1970 (2011)
17. Liu W, "A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter", Cancer Res, 65, pp.46~53 (2005)
18. Travis WD, "Histological typing of lung and pleural tumours. 3rd ed" (1999), Springer-Verlag
19. Therasse P, "New Guidelines to Evaluate the Response to Treatment in Solid Tumors", pp.205~216 (2000), Oxford University Press
20. Shigematsu H, "Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers", J Natl Cancer Inst, 97, pp.339~346 (2005)
21. Amador ML, "An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors", Cancer Res, 64, pp.9139~9143 (2004)
22. Liu W, "Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism", Clin Cancer Res, 9, pp.1009~1012 (2003)
23. 한세원, "Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer", PHARMACOGENETICS AND GENOMICS, 17, pp.313~319, LIPPINCOTT WILLIAMS & WILKINS
24. Puyo S, "Impact of EGFR gene polymorphisms on anticancer drug cytotoxicity in vitro", Mol Diagn Ther, 12, pp.225~234 (2008)

관련 논문AI추천